New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Deliverables

Open Research Data Pilot (1)

KOL Engagement, Communication & Dissemination

Engagement, communication & dissemination of recent development and progress on ATXA’s lead drug NTP42 including with key opinion leaders (KOLs) and other stakeholders of relevance to pulmonary arterial hypertension (PAH).

Publications

Peer reviewed articles (3)

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Pedro Mendes-Ferreira, Rui Adão, Carmen Brás-Silva, B. Therese Kinsella
Published in: European Journal of Pharmacology, 889, 2020, Page(s) 173658, ISSN 0014-2999
Publisher: Elsevier BV
DOI: 10.1016/j.ejphar.2020.173658

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Author(s): Eamon P. Mulvaney, Áine G. O'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Published in: Experimental and Molecular Pathology, 110, 2019, Page(s) 104277, ISSN 0014-4800
Publisher: Academic Press
DOI: 10.1016/j.yexmp.2019.104277

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Published in: BMC Pulmonary Medicine, 20/1, 2020, ISSN 1471-2466
Publisher: BioMed Central
DOI: 10.1186/s12890-020-1113-2

Conference proceedings (2)

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Respiratory Journal, 2019, Page(s) PA5048
Publisher: European Respiratory Society

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Journal of Cardiology, 40, 2019, Page(s) P3670
Publisher: Oxford Academic